Underlying EBITDA as per updated guidance in May, so nothing to see there...
FY19 Outlook seems to be better considering the reduction in operating costs as per planned with a bit more than one third achieved already. Trading outlook as per below seems good too..standalone GP clinics LFL fall in sales seem to have decelerated..
Trading update as at week 6:
• 5.8% Group LFL sales growth
• 6.1% Group Retail LFL sales growth
• 5.2% Australian Vet LFL sales growth including negative LFL sales in standalone GP clinics of 0.5%
• 8.0% Group revenue growth
- Forums
- ASX - By Stock
- GXL
- Ann: FY18 Full Year Results - Investor Presentation
Ann: FY18 Full Year Results - Investor Presentation, page-2
-
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GXL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online